Best Urologists and Urinary Tract Doctors in Bronx, NY

Dr. Ojas Shah is the George F. Cahill Professor of Urology at Columbia University College of Physicians and Surgeons. He also serves as the Director of the Division of Endourology and Stone Disease at Columbia University Medical Center. His clinical and research interests include surgical and metabolic treatments of kidney stone disease, minimally invasive urologic surgery, upper urinary tract urothelial carcinoma (transitional cell carcinoma), ureteral strictures, ureteropelvic junction (UPJ) obstruction, ureteral/renal reconstructive surgery, and BPH (benign prostate hyperplasia). He serves as the principal investigator in many clinical research trials regarding the surgical or medical management of stone disease. He is a graduate of the Honors Program in Medical Education at Northwestern University School of Medicine. He completed his general surgical and urologic training at New York University Medical Center. He spent an additional year at Wake Forest University Health Sciences Center as a fellow in endourology, laparoscopy and metabolic stone disease. Dr. Shah is a nationally and internationally recognized expert in the medical and surgical management of patients with urinary stone disease. He recently served as a member of the American Urological Association's Surgical Management of Stones Guidelines Committee. He was also recently appointed to the American Board of Urology's Examination Committee. He is an active member of the Endourological Society, EDGE (Endourology Disease Group for Excellence) Research Consortium, and ROCK (Research on Calculous Kinetics) Society. Dr. Shah is an Assistant Editor for the Journal of Urology, the most highly cited and amongst the most respected international journals in the field. He is also co-editor of the 5th Edition of Taneja's Complications of Urologic Surgery which was released in 2018. Dr. Shah serves as the Director of the Endourology Fellowship at Columbia University Medical Center. He additionally has a strong focus on medical student and resident education, and served as the urology residency program director at NYU School of Medicine prior to joining Columbia. Dr. Shah is accepting new patients at Columbia University Medical Center (161 Fort Washington Avenue) and ColumbiaDoctors Midtown (51 West 51st Street).

James McKiernan, MD, is the John K. Lattimer Professor of Urology, and CEO, of ColumbiaDoctors. He also is the interim dean of Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues. For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer.

Dr. Izak Faiena MD, MSCR is a urologic oncologist with a specialized focus on prostate cancer. His expertise spans advanced diagnostic techniques, such as MRI fusion and transperineal biopsy, as well as cutting-edge treatments including focal therapy and robotic surgery. With a solid foundation from the Albert Einstein College of Medicine, where he graduated with Alpha Omega Alpha honors, Dr. Faiena went on to complete his urology residency at Rutgers Robert Wood Johnson Medical School. During this time, he earned multiple research awards for his contributions to prostate and bladder cancer studies. Following his residency, Dr. Faiena pursued a fellowship in urologic oncology and earned a Master's in Clinical Research from the esteemed UCLA Institute of Urologic Oncology and the Clinical and Translational Science Institute. His work here garnered significant research funding and resulted in impactful publications on clinical trials in urologic cancers. Currently, Dr. Faiena is dedicated to advancing the field of prostate cancer through innovative clinical trials, targeting both localized and advanced stages of the disease. His groundbreaking research has been featured in top national and international medical journals, reflecting his commitment to improving patient outcomes and advancing cancer care.